Complement Factor D Inhibitors
As part of Achillion’s dedication to advancing science, reprints of scientific presentations regarding Achillion’s novel complement factor D inhibitor platform are available here.
Included below are resources that were created as of the dates listed and that reflected management’s views as of such dates. The information contained therein should not be considered current and may not be accurate. Achillion assumes no obligation to update the information in the below resources.
INTERNATIONAL COMPLEMENT WORKSHOP PRESENTATIONSSeptember 5, 2016 Assessment of Complement-Mediated Bacterial Killing and the Effect of a Small Molecule Factor D Inhibitor in Vitro DOWNLOAD PDF September 5, 2016 Comparison of Complement Functional Assays: Differential Sensitivities of Hemolysis and Wieslab Assays to Levels of Complement Proteins C5, Factor B, and Factor D DOWNLOAD PDF
EHA 2016 PRESENTATIONJune 9, 2016 An Orally Administered Small Molecule Factor D Inhibitor (ACH-4471) For Treatment of PNH, C3G and Complement–Mediated Diseases: Interim Phase 1 Results In Healthy Volunteers DOWNLOAD PDF
ASH 2015 PRESENTATIONS
Complement Factor D Symposium, hosted by Achillion. Event held Sunday, December 6, 2015 during the American Society of Hematology (ASH) Annual Meeting in Orlando, FL.
Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, provided the opening remarks at the first Complement Symposium, hosted by Achillion, which was held in Orlando, Florida during the American Society of Hematology 2015 Annual Meeting, December 6, 2015.
Dr. Peter Densen, M.D., Professor of Internal Medicine – Infectious Disease, University of Iowa, provided a detailed look at the role of thecomplement system and the relative risks of infection associated with immune modulation.
Dr. Scott Barnum, Ph.D., Department of Microbiology at the University of Alabama at Birmingham, presented a review of complement immune-biology and the roles of the classical, lectin, and alternative pathways.
Dr. David Apelian, M.D., Ph.D., Chief Medical Officer of Achillion Pharmaceuticals, discussing the nomination of ACH-4471, small-molecule complement factor D inhibitor, being developed for the treatment of ultra-rare diseases, including PNH.
ASH 2014 PRESENTATIONSDecember 8, 2014 Pharmacology of Complement Factor D Inhibitors ASH 2014 DOWNLOAD PDF December 8, 2014 Complement Factor D Inhibitors for PNH ASH 2014 DOWNLOAD PDF
Please note that the above resources were created as of the dates listed and that reflected management’s views as of such dates. The information contained therein should not be considered current and may not be accurate. Achillion assumes no obligation to update the information in the above resources.